Stryker’s OptaBlate, the company’s first basivertebral nerve ablation system earned FDA 510(k) clearance.
OptaBlate is used for a minimally invasive, target procedure for chronic vertebrogenic low back pain, according to a May 19 news release. It achieves at least a 1 centimeter lesion in seven minutes, is steerable and has microinfusion technology to improve precision.
“BVNA is a minimally invasive and innovative procedure that targets a key source of this pain, particularly in patients with specific MRI findings,” spine surgeon Jad Khalil, MD, said in the release. “Before BVNA, options for lasting relief were limited. For many, it offers meaningful improvement and can help avoid more aggressive treatments like surgery.”
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
